Applicants:

Anthony A. Sauvé and Vern L. Schramm

Filed:

January 4, 2002

Page 2

Amendments to the claims

Please cancel Claims 6-9, 12, 13, 16-21, 31, 32 without prejudice to applicants' right to pursue prosecution of these claims in a later-filed continuation or divisional application, amend Claims 1-3 and 34-37, and add new Claims 38-42, as follows.

1. (currently amended). A compound represented by the formula:

wherein

A is a <u>an N-linked</u> nicotinamide group, a <u>an N-linked unsubstituted</u> pyridyl group, a <u>an N-linked substituted</u> pyrimidyl group, an O-linked <u>unsubstituted</u> phenyl group, an O-linked <u>unsubstituted</u> pyridyl group, an O-linked <u>unsubstituted</u> pyridyl group, an O-linked <u>unsubstituted</u> pyridyl group, an O-linked <u>unsubstituted</u> pyrimidyl group, an S-linked <u>unsubstituted</u> phenyl group, an S-linked <u>unsubstituted</u> phenyl group, an S-linked <u>unsubstituted</u> pyridyl group, an S-linked <u>substituted</u> pyridyl group, an S-linked <u>unsubstituted</u> pyrimidyl group;

B is hydrogen, or a halogen, amino, or thiol group; C is hydrogen, or a halogen, amino, or thiol group; and D is a primary alcohol, hydrogen, or

Applicants:

Anthony A. Sauvé and Vern L. Schramm

Filed:

January 4, 2002

Page 3

an oxygen, nitrogen, carbon, or sulfur linked to

phosphate, a phosphoryl group, a pyrophosphoryl group, or adenosine monophosphate through a phosphodiester or carbon-, nitrogen-, or sulfur-substituted phosphodiester bridge, or to

adenosine diphosphate through a phosphodiester or carbon-, nitrogen-, or sulfur-substituted pyrophosphodiester bridge.

- 2 (currently amended). The compound of claim 1, wherein A is an N-linked aryl group nicotinamide group, an N-linked unsubstituted pyridyl group, an N-linked unsubstituted pyrimidyl group.
- 3 (currently amended). The compound of claim 2, wherein A is a an N-linked nicotinamide group, an N-linked unsubstituted pyridyl group or a an N-linked substituted pyridyl group.
 - 4 (original). The compound of claim 3, which is a nicotinamide 2'-deoxyriboside.
- 5 (original). The compound of claim 3, which is β -1'-nicotinamide-2'-deoxyribose, β -D-1'-nicotinamide-2'-deoxyribofuranoside, β -1'-pyridyl-2'-deoxyribose, or 5'-phospho-1'-pyridyl-deoxyribose.
 - 6-9 (canceled).
- 10 (original). The compound of claim 1, wherein both B and C are hydrogen, or either B or C is a halogen, amino, or thiol group and the other of B or C is hydrogen.
- 11 (original). The compound of claim 2, wherein both B and C are hydrogen, or either B or C is a halogen, amino, or thiol group and the other of B or C is hydrogen.

Applicants:

Anthony A. Sauvé and Vern L. Schramm

Filed:

January 4, 2002

Page 4

12-13 (canceled).

14 (original). The compound of claim 1, wherein D is a primary alcohol or hydrogen.

15 (original). The compound of claim 2, wherein D is a primary alcohol or hydrogen.

16-29 (canceled).

30 (previously presented). The compound of claim 3, wherein both B and C are hydrogen, or either B or C is a halogen, amino, or thiol group and the other of B or C is hydrogen.

31-32 (canceled).

- 33 (previously presented). The compound of claim 3, wherein D is a primary alcohol or hydrogen.
- 34 (currently amended). The compound of claim 4 10, wherein D is a primary alcohol or hydrogen.
- 35 (currently amended). The compound of claim $\frac{5}{11}$, wherein D is a primary alcohol or hydrogen.
- 36 (currently amended). A pharmaceutical composition comprising the compound of claim 3 1 and a pharmaceutically-acceptable carrier.

Applicants:

Anthony A. Sauvé and Vern L. Schramm

Filed:

January 4, 2002

Page 5

37 (currently amended). A pharmaceutical composition comprising the compound of claim $4 \underline{2}$ and a pharmaceutically-acceptable carrier.

38 (new). A pharmaceutical composition comprising the compound of claim 3 and a pharmaceutically-acceptable carrier.

39 (new). A pharmaceutical composition comprising the compound of claim 4 and a pharmaceutically-acceptable carrier.

40 (new). A pharmaceutical composition comprising the compound of claim 5 and a pharmaceutically-acceptable carrier.

41 (new). A pharmaceutical composition comprising the compound of claim 10 and a pharmaceutically-acceptable carrier.

42 (new). A pharmaceutical composition comprising the compound of claim 11 and a pharmaceutically-acceptable carrier.